Items Tagged ‘precision cancer medicines’

June 26th, 2017

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation


The U.S. Food and Drug Administration granted regular approvals to Tafinlar® (dabrafenib) and Mekinist® (trametinib) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. These are the first FDA approvals specifically for treatment of patients with BRAF V600E mutation-positive metastatic NSCLC. The […]

View full entry

Tags: dabrafenib, Lung Cancer, Lung Cancer - Non-Small Cell, mekinist, News, non-small cell lung cancer, precision cancer medicines, tafinlar, targeted therapy, trametinib